Kierah Bircham2021-06-28T11:44:17+01:00
Cycle Pharmaceuticals appoints Denise Moody as Chief Operating Officer
Holly Archer2021-05-25T17:41:24+01:00
Cycle Pharmaceuticals appoints Steve McCue as Chief Financial Officer
Holly Archer2021-05-17T18:52:30+01:00
Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors
Holly Archer2021-05-17T18:52:30+01:00
US FDA Grants Once Daily Dosing Option For NITYR (nitisinone) Tablets for HT-1 Patients
Holly Archer2021-05-17T18:52:31+01:00
Dr David Buckeridge Joins Cycle Group Holdings’ Board of Directors
Holly Archer2021-05-17T18:52:31+01:00
Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020
Holly Archer2021-05-17T18:52:31+01:00
Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)
Web_Admin2021-05-17T18:52:31+01:00
Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile
Holly Archer2021-05-17T18:52:31+01:00
Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA
Web_Admin2021-05-17T18:52:31+01:00